Strides Pharma Science has agreed to sell the biologics Unit-3 manufacturing facility of its associate company Stelis Biopharma to Syngene International for INR702 crore ($94m) in cash. Syngene will also invest up to INR100 crore to repurpose and revalidate the Bommasandra Industrial Area in Bengaluru site, which is being repurposed to produce monoclonal antibodies.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iqXog8f
via IFTTT
0 comments:
Post a Comment